Cancer Tissue Repository Launched

The Dana-Farber Cancer Institute will store tissue samples from patients with leukemia and lymphoma from which scientists can make patient-derived mouse models.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, RAMAOne method that is growing in popularity for testing drugs on specific cancer types is the creation of patient-derived xenografts (PDXs), in which researchers implant bits of cancerous tissue extracted from patients into mice for study. Today (April 11), the Dana-Farber Cancer Institute announced the launch of an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma. Researchers can register for the database, called the Public Repository of Xenografts (PRoXe), use its Web portal to search for PDX models of specific subtypes of blood cancers, and order frozen cells from which they can create xenograft mouse models.

“About 90 percent of compounds that show anti-cancer activity in pre-clinical tests don’t work when given to patients,” said Dana-Farber’s David Weinstock said in a press release. “By trying drugs in PDX models, we can ‘mimic’ large and expensive human clinical trials and get answers about efficacy more quickly, less expensively and without the need for patients to get investigational drugs that won’t work.” Weinstock and his colleagues published details of the new repository today (April 11) in Cancer Cell; a total of 95 different researchers from 14 institutions are listed as coauthors.

For now, PRoXe includes only blood cancers, which are easier to biopsy and successfully transplant than solid tumors. But Weinstock noted in the press release that he and his colleagues are now ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo